Effective regulatory strategies

Rare disease drugs utilize multiple regulatory programs, often simultaneously, to expedite clinical development and regulatory review. In this section, Parexel experts and former regulators share insights on winning FDA Breakthrough Therapy designation, common misconceptions about developing orphan cell and gene therapies, and how to conduct an efficient and successful development program for an orphan-designated drug in the EU.

Download the executive summary of the full report